| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Medicine, University of Texas Health Science Center, San Antonio, TX.
Correspondence to: Jan E. Patterson, MD, University of Texas Health Science Center, Department of Medicine, 7703 Floyd Curl Dr, Mail Code 7881, San Antonio, TX 78229-3900; e-mail: pattersonj{at}uthscsa.edu
The antimicrobial resistance problem in hospitals continues to worsen. In particular, extended-spectrum ß-lactamase–producing Klebsiella pneumoniae (ESBL-KP) and vancomycin-resistant enterococci (VRE) are significant causes of morbidity and mortality among critically ill patients. Treating infections caused by these pathogens presents therapeutic dilemmas. The association between broad-spectrum ß-lactam overutilization and selection for ESBL-KP has been appreciated for some time; several institutions have reported a decrease in the prevalence of ESBL-KP with a shift in antibiotic utilization from third-generation cephalosporins to other broad-spectrum drugs. Currently, optimal treatment of ESBL-KP includes the carbapenems, but widespread use of these drugs is expensive and may be associated with further selection of antibiotic resistance and/or superinfection with other inherently resistant pathogens. VRE are especially difficult organisms to treat because of their inherent and acquired resistance to most currently available antibiotics. The prevalence of VRE has also been documented to decrease upon a shift in antibiotic use from third-generation cephalosporins to broad-spectrum antibiotics of other classes. Thus, antibiotic utilization measures appear to contribute to the control of the emergence of multidrug-resistant pathogens such as ESBL-KP and VRE.
Key Words: antibiotic • antimicrobial • extended-spectrum ß-lactamase • multidrug resistance • outbreak • pathogen • resistance • vancomycin
This article has been cited by other articles:
|
|
 |
|
  S. N. S. Fonseca, S. R. Melon Kunzle, M. J. Junqueira, R. T. Nascimento, J. I. de Andrade, and A. S. Levin Implementing 1-Dose Antibiotic Prophylaxis for Prevention of Surgical Site Infection Arch Surg, November 1, 2006; 141(11): 1109 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Al Naiemi, E. R. Heddema, A. Bart, E. de Jonge, C. M. Vandenbroucke-Grauls, P. H. M. Savelkoul, and B. Duim Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit J. Antimicrob. Chemother., October 1, 2006; 58(4): 853 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. al Naiemi, A. Bart, M. D. de Jong, C. M. Vandenbroucke-Grauls, P. J. G. M. Rietra, Y. J. Debets-Ossenkopp, P. C. Wever, L. Spanjaard, A. J. Bos, and B. Duim Widely Distributed and Predominant CTX-M Extended-Spectrum {beta}-Lactamases in Amsterdam, The Netherlands. J. Clin. Microbiol., August 1, 2006; 44(8): 3012 - 3014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mangione-Smith, L. Wong, M. N. Elliott, L. McDonald, and J. Roski Measuring the Quality of Antibiotic Prescribing for Upper Respiratory Infections and Bronchitis in 5 US Health Plans Arch Pediatr Adolesc Med, August 1, 2005; 159(8): 751 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nathwani and A. Tice Ambulatory antimicrobial use: the value of an outcomes registry J. Antimicrob. Chemother., January 1, 2002; 49(1): 149 - 154. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
